Physician profile
Rodolfo E Chirinos
NPI 1255535431
$25,550.33
in general payments reported to CMS, 2019-2025
31 companies · $15K in 2025
The $15K reported for 2025 was more than what 93% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $833 · 2020: $472 · 2021: $367 · 2022: $661 · 2023: $4,279 · 2024: $3,525 · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $11K · Food and Beverage: $10K · Travel and Lodging: $1,942 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $11,000.00 |
| Food and Beverage | $10,266.39 |
| Travel and Lodging | $1,942.40 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $11,549.22 | 2025 | Vtama |
| Dermavant Sciences, INC. | $3,855.39 | 2022-2024 | Vtama |
| Abbvie INC. | $1,869.55 | 2019-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $1,112.30 | 2019-2025 | Tremfya |
| Galderma Laboratories, L.P. | $1,024.18 | 2023-2025 | Nemluvio, Twyneo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $717.43 | 2022-2025 | Spevigo |
| Amgen INC. | $685.32 | 2020-2025 | Otezla, Otezla |
| Ucb, INC. | $682.16 | 2022-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $609.11 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $452.18 | 2023-2024 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $450.85 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $410.83 | 2019-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $382.48 | 2020-2025 | |
| Genentech USA, INC. | $330.78 | 2019-2021 | |
| Botanix Sb INC | $196.45 | 2025 | Sofdra |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $195.90 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $156.87 | 2019-2025 | Cabtreo, Jublia, Arazlo |
| Genzyme Corporation | $150.77 | 2020-2023 | |
| Incyte Corporation | $120.48 | 2024-2025 | Opzelura |
| Almirall LLC | $115.01 | 2021-2025 | Klisyri, Seysara |
| Biofrontera INC. | $113.36 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
| Leo Pharma INC. | $107.67 | 2020-2025 | Spevigo |
| Kerecis Limited | $98.61 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Strata Skin Sciences, INC. | $42.84 | 2024 | Xtrac |
| Arcutis Biotherapeutics, INC. | $33.42 | 2025 | Zoryve |
| Verrica Pharmaceuticals INC. | $20.82 | 2024 | Ycanth |
| Paratek Pharmaceuticals, INC. | $19.17 | 2025 | Nuzyra |
| Merck Sharp & Dohme LLC | $13.80 | 2019 | |
| Nabriva Therapeutics, Plc | $13.44 | 2021 | |
| Icad, INC | $12.73 | 2023 | Axxent Surface Controller |
| Mayne Pharma Commercial LLC | $7.21 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rodolfo Chirinos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.